SI-BONE stock gained 9.57 percent after a director sold shares

Published on 10/06/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SI-BONE stock posted Q2 2026 revenue of USD 56.01 million versus USD 55.34 million consensus on August 3. Analysts set a USD 24.17 target.

SIBN, US8257041090, Illustration mit AI erstellt.

SI-BONE stock (ISIN US8257041090) was last at USD 19.81 on Nasdaq on October 5, 2026, up 9.57 percent from the prior close. The move followed disclosure that director Jeffrey Dunn sold 20,000 shares for USD 369,400 on October 1 under a pre-arranged trading plan, as Investing.com reported on October 5, 2026.

Insider sale meets a strong session

The disclosed transaction was executed at a weighted average price of USD 18.47, while the stock reached USD 19.81 on October 5, 2026. The filing also showed that Dunn exercised 20,000 options at USD 4.68, leaving him with 16,057 directly held shares.

SI-BONE's market capitalization stood at USD 878.6 million on October 5, 2026. Its 632,022-share volume exceeded the 612,975-share average cited in the same market report, adding a concrete measure to the session's activity.

Quarterly growth beats the estimate

SI-BONE reported Q2 2026 revenue of USD 56.01 million, compared with analyst expectations of USD 55.34 million, while diluted EPS was a loss of USD 0.09 versus a consensus loss of USD 0.15, according to MarketBeat in its September 28, 2026 report. Revenue therefore exceeded the estimate by USD 0.67 million, while the adjusted loss was USD 0.06 per share smaller than expected.

The operating picture is improving, but profitability remains the key test. SI-BONE's Q2 2026 net loss was USD 4.09 million, and operating cash flow was positive at USD 0.78 million for the quarter, according to the latest financial results.

Analysts see further upside

MarketBeat describes a Moderate Buy consensus from seven covering research firms, with six Buy ratings and one Sell rating. The average 12-month price target is USD 24.17, which lies 22.0 percent above the October 5, 2026 Nasdaq price, according to MarketBeat.

Individual targets also moved higher in August. Truist raised its target from USD 21.00 to USD 23.00, UBS lifted its target from USD 24.00 to USD 25.00, and TD Cowen increased its target from USD 18.00 to USD 20.00, all cited by MarketBeat in its October 5, 2026 coverage.

Stock remains below its yearly high

SI-BONE stock was last at USD 19.81 on Nasdaq on October 5, 2026. The price sits within a 52-week range of USD 11.48 to USD 21.89, leaving quarterly execution, cash generation and new product adoption as the central operating markers.